BibTex format
@inproceedings{Yong:2018:10.1182/blood-2018-99-116624,
author = {Yong, K and Hinsley, S and Sherratt, D and Kendall, J and Brown, SR and Flanagan, L and Williams, C and Cavenagh, J and Kaiser, M and Rabin, NK and Ramasamy, K and Garg, M and Auner, HW and Hawkins, SF and Bygrave, C and De, Tute RM and Morgan, G and Davies, FE and Owen, RG},
doi = {10.1182/blood-2018-99-116624},
publisher = {AMER SOC HEMATOLOGY},
title = {Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk <i>Five</i> Study},
url = {http://dx.doi.org/10.1182/blood-2018-99-116624},
year = {2018}
}
RIS format (EndNote, RefMan)
TY - CPAPER
AU - Yong,K
AU - Hinsley,S
AU - Sherratt,D
AU - Kendall,J
AU - Brown,SR
AU - Flanagan,L
AU - Williams,C
AU - Cavenagh,J
AU - Kaiser,M
AU - Rabin,NK
AU - Ramasamy,K
AU - Garg,M
AU - Auner,HW
AU - Hawkins,SF
AU - Bygrave,C
AU - De,Tute RM
AU - Morgan,G
AU - Davies,FE
AU - Owen,RG
DO - 10.1182/blood-2018-99-116624
PB - AMER SOC HEMATOLOGY
PY - 2018///
SN - 0006-4971
TI - Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk <i>Five</i> Study
UR - http://dx.doi.org/10.1182/blood-2018-99-116624
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454837601015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
ER -